CIK 0001840748
LVTX LAVA Therapeutics NV
Insider trading from SEC Form 4. Last filing Feb 18, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Signals
Open-market buys and sells at LAVA Therapeutics NV, scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 10 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 13, 2025 | Jay T. Backstrom director | AGrant or award Common Shares (Right to Buy)derivative | +33,390 | $0.00 | $0 | 33,390 | Feb 18, 2025 |
| Feb 13, 2025 | Kapil Dhingra director | AGrant or award Common Shares (Right to Buy)derivative | +33,390 | $0.00 | $0 | 33,390 | Feb 18, 2025 |
| Feb 13, 2025 | Stephen A Hurly Chief Executive Officer | AGrant or award Share Options (Right to Buy)derivative | +335,100 | $0.00 | $0 | 335,100 | Feb 18, 2025 |
| Feb 13, 2025 | Peter A Kiener director | AGrant or award Common Shares (Right to Buy)derivative | +33,390 | $0.00 | $0 | 33,390 | Feb 18, 2025 |
| Feb 13, 2025 | Christy J. Oliger director | AGrant or award Common Shares (Right to Buy)derivative | +33,390 | $0.00 | $0 | 33,390 | Feb 18, 2025 |
| Feb 13, 2025 | Charles Q Morris Chief Medical Officer | AGrant or award Share Options (Right to Buy)derivative | +130,850 | $0.00 | $0 | 130,850 | Feb 18, 2025 |
| Feb 13, 2025 | Fred M Powell Chief Financial Officer | AGrant or award Share Options (Right to Buy)derivative | +124,700 | $0.00 | $0 | 124,700 | Feb 18, 2025 |
| Feb 13, 2025 | James Noble director | AGrant or award Common Shares (Right to Buy)derivative | +33,390 | $0.00 | $0 | 33,390 | Feb 18, 2025 |
| Feb 13, 2025 | Mary E. Wadlinger director | AGrant or award Common Shares (Right to Buy)derivative | +33,390 | $0.00 | $0 | 33,390 | Feb 18, 2025 |
| Feb 13, 2025 | Karen J Wilson director | AGrant or award Common Shares (Right to Buy)derivative | +33,390 | $0.00 | $0 | 33,390 | Feb 18, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Jay T. Backstromceo, officer, director
- Kapil Dhingradirector
- Stephen A HurlyChief Executive Officer
- Peter A Kienerdirector
- Charles Q MorrisChief Medical Officer
- James Nobledirector
- Christy J. Oligerdirector
- Fred M PowellChief Financial Officer
- Karen J Wilsondirector
- Mary E. Wadlingerdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.